Question 1

What are the potential side effects of MRG001 that I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) clinical trial (NCT05155839). Contact the study team or your healthcare provider for specific answers.

Question 2

How does MRG001 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) clinical trial (NCT05155839). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the trial visits look like, and how often will I need to come in?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) clinical trial (NCT05155839). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) clinical trial (NCT05155839). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) clinical trial (NCT05155839). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any specific eligibility criteria that I should be concerned about?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) clinical trial (NCT05155839). Contact the study team or your healthcare provider for specific answers.

What this study is about